

Freedom of Information Act 2000 - Request Reference FoI/21/511
Biologic Treatments for Dermatological and Rheumatological Conditions

Information Requested:

1. How many patients were treated in October 2021 (or latest available month) by the dermatology department with the following drugs:

Abrocitinib (Cibinqo)	0
Baricitinib (Olumiant)	2
Bimekizumab (Bimzelx)	2
Brodalumab (Kyntheum)	5
Dupilumab (Dupixent)	57
Ixekizumab (Taltz)	18
Risankizumab (Skyrizi)	21
Guselkumab (Tremfya)	12
Secukinumab (Cosentyx)	35
Tildrakizumab (Ilumetri)	2
Tralokinumab (Adtralza)	2
Ustekinumab (Stelara)	43

2. How many patients were treated in October 2021 (or latest available month) by the rheumatology department with the following drugs:

Baricitinib (Olumiant)	42
Filgotinib (Jyseleca)	0
Guselkumab (Tremfya)	0
Ixekizumab (Taltz)	6
Secukinumab (Cosen)	28
Tofacitinib (Xeljanz)	7
Upadacitinib (Rinvoq)	2
Ustekinumab (Stelara)	16

